MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib

BACKGROUND: Triple-negative breast cancers (TNBC) are heterogeneous cancers with poor prognosis. We aimed to determine the clinical relevance of membrane type-4 matrix metalloproteinase (MT4-MMP), a membrane type matrix metalloproteinase that interacts with epidermal growth factor receptor (EGFR) ov...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Cancer
Auteurs principaux: Yip, Cassandre, Foidart, Pierre, Somja, Joan, Truong, Alice, Lienard, Mehdi, Feyereisen, Emilie, Schroeder, Hélène, Gofflot, Stéphanie, Donneau, Anne-Françoise, Collignon, Joëlle, Delvenne, Philippe, Sounni, Nor Eddine, Jerusalem, Guy, Noël, Agnès
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2017
Sujets:
Translational Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355928/
https://ncbi.nlm.nih.gov/pubmed/28196064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.23
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires